CN101999001B - 疾病标志物及其用途 - Google Patents

疾病标志物及其用途 Download PDF

Info

Publication number
CN101999001B
CN101999001B CN2009801123932A CN200980112393A CN101999001B CN 101999001 B CN101999001 B CN 101999001B CN 2009801123932 A CN2009801123932 A CN 2009801123932A CN 200980112393 A CN200980112393 A CN 200980112393A CN 101999001 B CN101999001 B CN 101999001B
Authority
CN
China
Prior art keywords
ifi44l
ifn
ifi6
isg15
ifit1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801123932A
Other languages
English (en)
Chinese (zh)
Other versions
CN101999001A (zh
Inventor
Y·姚
C·莫尔豪斯
B·希格斯
B·加莱
S·A·格林柏格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary, MedImmune Vaccines Inc filed Critical Massachusetts Eye and Ear Infirmary
Publication of CN101999001A publication Critical patent/CN101999001A/zh
Application granted granted Critical
Publication of CN101999001B publication Critical patent/CN101999001B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801123932A 2008-02-08 2009-02-06 疾病标志物及其用途 Active CN101999001B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US696308P 2008-02-08 2008-02-08
US61/006,963 2008-02-08
PCT/US2009/033407 WO2009100342A2 (en) 2008-02-08 2009-02-06 Disease markers and uses thereof

Publications (2)

Publication Number Publication Date
CN101999001A CN101999001A (zh) 2011-03-30
CN101999001B true CN101999001B (zh) 2013-11-20

Family

ID=40952717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801123932A Active CN101999001B (zh) 2008-02-08 2009-02-06 疾病标志物及其用途

Country Status (12)

Country Link
US (1) US20110262928A1 (https=)
EP (2) EP2848702A1 (https=)
JP (1) JP2011511804A (https=)
KR (1) KR20110005783A (https=)
CN (1) CN101999001B (https=)
AU (1) AU2009212216B2 (https=)
BR (1) BRPI0908065A2 (https=)
CA (1) CA2714410A1 (https=)
ES (1) ES2529593T3 (https=)
MX (1) MX2010008698A (https=)
SG (1) SG188147A1 (https=)
WO (1) WO2009100342A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2666873B1 (en) * 2007-07-12 2016-03-09 The Brigham and Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
JP2012522508A (ja) * 2009-03-31 2012-09-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロｒｎａ
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
US20130022985A1 (en) * 2010-04-08 2013-01-24 Hiroyuki Yoshitomi Examination method to determine contraction or activity of diseases related immune system or joint system
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2013020926A1 (en) * 2011-08-11 2013-02-14 Febit Holding Gmbh Complex sets of mirnas as non-invasive biomarkers for psoriasis
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP2653554A1 (en) * 2012-04-17 2013-10-23 Istituto Nazionale Di Genetica Molecolare-INGM Immune response biomarkers
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
EP3013985A4 (en) * 2013-06-28 2017-07-19 Acumen Research Laboratories Pte. Ltd. Sepsis biomarkers and uses thereof
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
WO2019210179A1 (en) * 2018-04-27 2019-10-31 Stemline Therapeutics, Inc. Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3)
CN110085282A (zh) * 2019-04-23 2019-08-02 华中师范大学 核酸结构中核苷酸与核苷酸相互作用预测的方法
CN110108880A (zh) * 2019-05-30 2019-08-09 四川大学华西医院 Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110161235B (zh) * 2019-06-26 2022-04-12 江苏省中医院 三种血清蛋白联合用于强直性脊柱炎诊断的用途
BR112022006441A2 (pt) * 2019-10-04 2022-07-05 Univ Michigan Regents Métodos para determinar a capacidade de resposta à terapia antifator de necrose tumoral no tratamento da psoríase
CN111378742A (zh) * 2020-04-16 2020-07-07 嘉兴程瑞医药科技有限公司 microRNA生物标志物及其在制备自身免疫疾病检测试剂盒中的应用
CN113388677A (zh) * 2021-06-17 2021-09-14 河北医科大学第二医院 包括ifi44的干燥症诊断标志物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019219A2 (en) * 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
WO2008070137A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US7833795B2 (en) * 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019219A2 (en) * 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
WO2008070137A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus (abstract 1315);D. Wallace, M. Petri, N. Olsen, K. Kirou, G. Dennis, et al.;《ARTHRITIS & RHEUMATISM》;20071231;第56卷;全文 *
Type I Interferon–Inducible Gene Expression in Blood Is Present and Reflects Disease Activity in Dermatomyositis and Polymyositis;Ronan J. Walsh, Sek Won Kong, et al.;《ARTHRITIS & RHEUMATISM》;20071130;第56卷(第11期);表2，图1-图4 *

Also Published As

Publication number Publication date
SG188147A1 (en) 2013-03-28
MX2010008698A (es) 2010-12-20
EP2848702A1 (en) 2015-03-18
AU2009212216B2 (en) 2015-04-09
AU2009212216A1 (en) 2009-08-13
CN101999001A (zh) 2011-03-30
JP2011511804A (ja) 2011-04-14
WO2009100342A2 (en) 2009-08-13
ES2529593T3 (es) 2015-02-23
EP2252703A4 (en) 2011-12-21
EP2252703B1 (en) 2014-11-05
US20110262928A1 (en) 2011-10-27
EP2252703A2 (en) 2010-11-24
KR20110005783A (ko) 2011-01-19
BRPI0908065A2 (pt) 2015-08-11
WO2009100342A3 (en) 2009-12-30
CA2714410A1 (en) 2009-08-13
HK1150063A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
CN101999001B (zh) 疾病标志物及其用途
AU2007327995B2 (en) Interferon alpha-induced pharmacodynamic markers
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
AU2010289383B2 (en) Type 1 interferon diagnostic
CN101594882A (zh) 干扰素α诱导的药代动力学标记物
US20110287022A1 (en) Interferon alpha-induced pharmacodynamic markers
US20100261172A1 (en) Interferon alpha-induced pharmacodynamic markers
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
HK1150063B (en) Disease markers and uses thereof
AU2015203772A1 (en) Disease markers and uses thereof
AU2014200127A1 (en) Interferon alpha-induced pharmacodynamic markers
HK1140406A (en) Interferon alpha-induced pharmacodynamic markers
AU2014200128A1 (en) Interferon alpha-induced pharmacodynamic markers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant